

POCKET BOOKS FOR CANCER SUPPORTIVE CARE

Febrile Neutropenia

Jean A Klastersky

Febrile Neutropenia

Febrile Neutropenia

Jean A Klastersky

Consultant, Medical Oncology

Institut Jules Bordet

Centre des Tumeurs de l'Université Libre de Bruxelles

Brussels

Belgium



Springer Healthcare

Published by Springer Healthcare Ltd, 236 Gray's Inn Road, London, WC1X 8HB, UK.

www.springerhealthcare.com

© 2014 Springer Healthcare, a part of Springer Science+Business Media.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means electronic, mechanical, photocopying, recording or otherwise without the prior written permission of the copyright holder.

British Library Cataloguing-in-Publication Data.

A catalogue record for this book is available from the British Library.

ISBN 9781907673696

Although every effort has been made to ensure that drug doses and other information are presented accurately in this publication, the ultimate responsibility rests with the prescribing physician. Neither the publisher nor the authors can be held responsible for errors or for any consequences arising from the use of the information contained herein. Any product mentioned in this publication should be used in accordance with the prescribing information prepared by the manufacturers. No claims or endorsements are made for any drug or compound at present under clinical investigation.

Project editor: Tess Salazar

Production: Patty Goldstein

Printed in Great Britain by Latimer Trend

Contents

Author biography	vii
Abbreviations	viii
1 Introduction	1
Historical perspectives: why empirical therapy?	1
Current microbiological epidemiology	2
Common clinical presentations	6
Present achievements	7
Future directions	7
References	10
2 Prevention of febrile neutropenia	13
Risk factors predicting febrile neutropenia	13
Chemoprophylaxis	14
The use of granulopoietic colony stimulating	16
References	25
3 Prediction of the risk of complications associated with febrile neutropenia	27
Types and incidence of complications	27
Prediction of the individual risk of complications	28
Laboratory data and the Multinational Association of Supportive Cancer Care score index	29
The predictive value of the Multinational Association of Supportive Cancer Care index	31
References	34
4 Management of the low-risk patients	35
Orally administered antimicrobial therapy	35
Early hospital discharge	37
References	41

5	Management of the non-low-risk patients with febrile neutropenia	43
	Predicting the non-low-risk patients with febrile neutropenia	43
	Use of biological or microbiological parameters to predict poor outcome	44
	Antibiotic management of non-low-risk patients	45
	Non-low-risk patients at particular risk of septic complications	46
	Follow-up and assessment of response	49
	References	52
6	Management of persistent fever in patients with neutropenia despite empirical antibiotic administration	55
	The causes of persistent fever	55
	Prevention of invasive-fungal infection	56
	Management of suspected invasive-fungal infection	57
	Therapy of established invasive-fungal infections	60
	References	61
7	Costs associated with febrile neutropenia	63
	General conditions	63
	Magnitude of the costs associated with febrile neutropenia	63
	Reducing the cost of febrile neutropenia	64
	References	68
8	At the extremes of age: febrile neutropenia in children and elderly	69
	Febrile neutropenia in the pediatric population	69
	Febrile neutropenia in the elderly	70
	References	73

Author biography

Jean A Klastersky, MD, PhD, is head of the Department of Medicine at the Institut Jules Bordet in Brussels and has been Professor of Medicine, Medical Oncology, and Physical Diagnosis at the Université Libre de Bruxelles since 1977.

Professor Klastersky was an Intern and Resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965 where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements). From 1967 to 1968 he was Chief-Resident at Boston City Hospital and then a Research Fellow and Assistant in Medicine at Thorndike Memorial Laboratory, Harvard Medical School. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970 before taking up his current position in 1977.

Professor Klastersky was a founder member of the European Lung Cancer Working Party and has been its President since 1978. He was President (and founding member) of the International European Organisation for Research and Treatment of Cancer (EORTC) Antimicrobial Therapy Project Group between 1979 and 1987 and the Group's Secretary General from 1987 to 2000. He was President (and founding member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000, and has been Visiting Professor of Medical Oncology at Charles University, Prague since 1994.

Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Disease Society of America, the International Association for the Study of Lung Cancer, and various other international and national medical and/or oncological societies.

Abbreviations

ANC	absolute neutrophil count
ASCO	American Society of Clinical Oncology
BCG	Bacillus Calmette–Guérin
CNS	central nervous system
CRP	C-reactive protein
CT	computed tomography
ECOG	Eastern Cooperative Oncology Group
EORTC	European Organisation for Research and Treatment of Cancer
ESMO	European Society of Medical Oncology
FAC	fluorouracil, doxorubicin, cyclophosphamide
FN	febrile neutropenia
FUO	fever of unknown origin
G-CSF	granulocyte colony-stimulating factor
ID	infectious disease
IDSA	Infectious Diseases Society of America
IFD	invasive-fungal diseases
IL	interleukin
MASCC	Multinational Association for Supportive Care in Cancer
PCR	polymerase chain reaction
Pros	prospective study
RCT	randomized clinical trial
Retro	retrospective study
SMX	sulfamethoxazole
TAC	docetaxel, doxorubicin, cyclophosphamide
TMP	trimethoprim
VZV	varicella-zoster virus